Kleinert S, Tony H P
Fachbereich Rheumatologie/Immunologie, Medizinische Klinik 2, Universitätsklinikum Würzburg, Oberdürrbacher Str. 6, 97080 Würzburg, Deutschland.
Internist (Berl). 2012 Sep;53(9):1028-37. doi: 10.1007/s00108-012-3030-9.
Rheumatic diseases are manifested in all ages. First manifestations of gout are frequent between the ages of 40-60 years. Furthermore, the incidence of rheumatoid arthritis increases as well as anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitides. Recently new treatment options for gout were established but colchicine, which has been used to treat gout for a long time was also further optimized in its use. Remarkable advantages in the treatment of rheumatoid arthritis towards remission have been made by the introduction of biological agents 10 years ago. In granulomatosis with polyangiitis (formerly Wegener's disease) therapeutic optimization has led to a reduction in toxicity and rituximab has proven to be an effective treatment option.
风湿性疾病在各个年龄段均有表现。痛风的首发症状常见于40至60岁之间。此外，类风湿关节炎以及抗中性粒细胞胞浆抗体（ANCA）相关血管炎的发病率也在增加。最近，痛风有了新的治疗选择，而长期用于治疗痛风的秋水仙碱在使用上也得到了进一步优化。10年前引入生物制剂后，在类风湿关节炎的缓解治疗方面取得了显著进展。在肉芽肿性多血管炎（以前称为韦格纳肉芽肿病）中，治疗的优化降低了毒性，利妥昔单抗已被证明是一种有效的治疗选择。
